Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2015

View Archived Issues

Gene therapy from the NEI receives FDA orphan drug designation

DDX3X inhibition inhibits cancer cell proliferation

Biomarkers of cardiovascular risk identified in patients with dysglycemia

Lilly and Merck & Co. expand immuno-oncology collaboration

Thermo Fisher Scientific signs agreement to develop NSCLC universal companion diagnostic

Enumeral Biomedical reports data on its allosteric anti-PD-1 antibodies

Interim phase Ib/II data for ND-L02-s0201

Ignyta and Moffitt Cancer Center collaborate on RXDX-106

Actair house dust mite tablets launched in Japan

NIAID and GSK collaborate on broadly neutralizing antibody strategy for HIV infection

Hapten Sciences plans phase I trial of urushiol vaccine

Study shows potential new indication for miRNA biomarker

FDA approves Ninlaro for multiple myeloma

GSK-1278863 is safe and effective in Japanese, anemic hemodialysis patients

Pfizer discloses TrkA inhibitors

Centaurus BioPharma patents BTK inhibitors

Hyundai Pharmaceutical reports GPR119 agonists

TRIA Bioscience presents synthetic hapten vaccines

Bluebird bio presents improved CARs for T-cell therapies

Eiger BioPharmaceuticals and Celladon to merge

Lupin patents CaSR agonists

FDA grants regular approval to Tafinlar plus Mekinist for melanoma

CTI BioPharma initiates rolling NDA submission for pacritinib in myelofibrosis

European Commission approves Ionsys for acute postoperative pain

Janssen submits NDA for Invokamet XR for type 2 diabetes

Horizon Pharma withdraws Depomed acquisition offer

FDA clears first-in-human study of GeneOne and Inovio's MERS vaccine

EMA committee recommends European approval of Wakix for narcolepsy

Pfizer and Allergan announce merger agreement

Oxaliplatin and capecitabine regimen approved for gastric cancer adjuvant therapy in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...